Supernus Pharmaceuticals Inc. Common Stock (SUPN)

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (P…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

778

Website

www.supernus.com

Fundamentals

1-day range

$43.13$44.3

Market cap

$2.67B

P/E (trailing)

—

P/E (forward)

9.80

EPS (trailing)

$-1.91

Dividend yield

—

Beta

0.56

Avg. volume

857.5K

Forecasts

4 analyst ratings

Supernus Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SUPN

  Supernus Pharmaceuticals Inc. Common Stock

  $43.76

  ▼ 0.97%
  Market cap $2.67BP/E —
  $42.45$59.68
• IMNM

  Immunome Inc. Common Stock

  $27.57

  ▼ 4.50%
  Market cap $2.61BP/E —
  $8.67$30.06
• TRVI

  Trevi Therapeutics Inc. Common Stock

  $16.78

  ▼ 6.60%
  Market cap $2.54BP/E —
  $6.93$20.22
• RARE

  Ultragenyx Pharmaceutical Inc. Common Stock

  $25.62

  ▼ 2.46%
  Market cap $2.46BP/E —
  $18.29$39.89
• IRON

  Disc Medicine Inc. Common Stock

  $80.01

  ▼ 3.08%
  Market cap $2.93BP/E —
  $40$99.5
• NKTR

  Nektar Therapeutics Common Stock

  $72.57

  ▼ 2.66%
  Market cap $2.38BP/E —
  $27.87$109
• PGEN

  Precigen Inc. Common Stock

  $6.94

  ▼ 3.55%
  Market cap $2.36BP/E —
  $2.99$7.72

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
  benzinga · 8/17/2026
• Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
  Benzinga · 8/17/2026
• Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow
  SeekingAlpha · 8/7/2026
• SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
  Yahoo · 8/7/2026
• New Strong Buy Stocks for August 7th
  Yahoo · 8/7/2026
• Best Value Stocks to Buy for August 7th
  Yahoo · 8/7/2026
• Carillon Chartwell Small Cap Growth Fund Q2 2026 Portfolio Review
  SeekingAlpha · 8/7/2026
• Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...
  Yahoo · 8/5/2026
• INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
  Yahoo · 8/4/2026

• Jonathan Rubin · August 12, 2026 · Option Exercise

  750
• Jonathan Rubin · August 12, 2026 · Tax Withholding

  363 @ $46.57
• Frank Mottola · August 12, 2026 · Option Exercise

  1.6K
• Frank Mottola · August 12, 2026 · Tax Withholding

  797 @ $46.57
• Jack A. Khattar · August 12, 2026 · Option Exercise

  29.8K
• Jack A. Khattar · August 12, 2026 · Tax Withholding

  12.6K @ $46.57
• Padmanabh P. Bhatt · August 12, 2026 · Option Exercise

  2.5K
• Padmanabh P. Bhatt · August 12, 2026 · Tax Withholding

  1.2K @ $46.57
• Timothy C. Dec · August 12, 2026 · Option Exercise

  1.3K
• Timothy C. Dec · August 12, 2026 · Tax Withholding

  604 @ $46.57
• Jonathan Rubin · July 29, 2026 · Grant

  750
• Frank Mottola · July 29, 2026 · Grant

  1.6K
• Jack A. Khattar · July 29, 2026 · Grant

  29.8K
• Padmanabh P. Bhatt · July 29, 2026 · Grant

  2.5K
• Timothy C. Dec · July 29, 2026 · Grant

  1.3K

Institutional Ownership

March 31, 2026

Total shares held

54.23M

Total value held

$2.69B

Institutional holders

319